SeaStar_SM_LogoCard.png
SeaStar Medical to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
31 janv. 2023 08h00 HE | SeaStar Medical Holding Corporation
DENVER, Jan. 31, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital...
SeaStar_SM_LogoCard.png
SeaStar Medical Bolsters Operational Expertise with Appointment of Thomas R. Mullen as Vice President of Operations and Product Development
02 déc. 2022 09h05 HE | SeaStar Medical Holding Corporation
DENVER, COLORADO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary...
SeaStar_SM_LogoCard.png
SeaStar Medical Appoints Rick Barnett as Chairman of the Board of Directors
29 nov. 2022 09h05 HE | SeaStar Medical Holding Corporation
DENVER, COLORADO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq:ICU), (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary...
SeaStar_SM_LogoCard.png
SeaStar Medical’s Lead Product Candidate, the Selective Cytopheretic Device (SCD), Included in Consensus Statement for Pediatric Acute Kidney Injury in First Pediatric Acute Disease Quality Initiative (ADQI) Meeting
07 nov. 2022 12h30 HE | SeaStar Medical Holding Corporation
– The SCD is currently being evaluated by the FDA for a Humanitarian Device Exemption (HDE) marketing approval for use in children (> 20 kgs) with AKI – The Company expects the FDA to complete...